The DOI matches its Crossref record; 63 of the 63 references it cites were found in a registry or an index.
TOX transcriptionally and epigenetically programs CD8+ T cell exhaustion
Open accessAbstract
Exhausted CD8+ T (T ex) cells in chronic infections and cancer have limited effector function, high co-expression of inhibitory receptors and extensive transcriptional changes compared with effector (T eff) or memory (T mem) CD8+ T cells. T ex cells are important clinical targets of checkpoint blockade and other immunotherapies. Epigenetically, T ex cells are a distinct immune subset, with a unique chromatin landscape compared with T eff and T mem cells. However, the mechanisms that govern the transcriptional and epigenetic development of T ex cells remain unknown. Here we identify the HMG-box transcription factor TOX as a central regulator of T ex cells in mice. TOX is largely dispensable for the formation of T eff and T mem cells, but it is critical for exhaustion: in the absence of TOX, T ex cells do not form. TOX is induced by calcineurin and NFAT2, and operates in a feed-forward loop in which it becomes calcineurin-independent and sustained in T ex cells. Robust expression of TOX therefore results in commitment to T ex cells by translating persistent stimulation into a distinct T ex cell transcriptional and epigenetic developmental program.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“which transcriptionally and epigenetically programs CD8+ T cell exhaustion [52].”
From Single-cell transcriptome reveals the reprogramming of immune microenvironment during the transition from MASH to HCC (2025) · cites this paper as [52]
The cited source says what the claim attributes to it.
In the citing paper
“Treatment‐induced declines in PD‐1+ CD8 T cells are consistent with the possibility that thymus regeneration treatment epigenetically reprograms “exhausted” CD8 T cells (T EX), a recently characterized distinct PD‐1+ CD8 population (Khan et al., 2019).”
From Reversal of epigenetic aging and immunosenescent trends in humans. (2019) · cites this paper as Khan et al., 2019
In the citing paper
“The excessive antigen density and kinetics of antigen exposure in solid tumors can drive exhaustion or dysfunction of T cells (Khan et al., 2019; Wherry, 2011).”
From Pooled Knockin Targeting for Genome Engineering of Cellular Immunotherapies (2020) · cites this paper as Khan et al., 2019
In the citing paper
“Furthermore, bulk RNA-seq analysis of isolated cells (ND naïve, HFHC Tem, HFHC Trm, and RES Trm) revealed that both Trm subsets from HFHC mice and RES mice expressed core signature genes of Trm21–24 with exceptions including Itgae (CD103) and Eomes (Fig. 4d).”
From CD8+ tissue-resident memory T cells promote liver fibrosis resolution by inducing apoptosis of hepatic stellate cells (2021) · cites this paper as [24]
In the citing paper
“CD8 T cells are typically regarded as a uniform population with cytotoxic function; however, recent studies have highlighted the diversity of the CD8 T-cell population (5)(6)(7)(8)(9).”
From The Next Decade of Immune Checkpoint Therapy (2021) · cites this paper as [5]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
Control of Regulatory T Cell Development by the Transcription Factor Foxp3
Hori, S., Nomura, T., & Sakaguchi, S. (2003) · Science · doi:10.1126/science.1079490 · Cited by 8,187
Foxp3 programs the development and function of CD4+CD25+ regulatory T cells
Fontenot, J. D., Gavin, M. A., & Rudensky, A. Y. (2003) · Nature Immunology · doi:10.1038/ni904 · Cited by 7,745
Buenrostro, J. D., Giresi, P. G., Zaba, L. C., Chang, H. Y., & Greenleaf, W. J. (2013) · Nature Methods · doi:10.1038/nmeth.2688 · Cited by 6,422
Molecular and cellular insights into T cell exhaustion
Wherry, E. J., & Kurachi, M. (2015) · Nature Reviews Immunology · doi:10.1038/nri3862 · Cited by 4,652
Self-citationMaster Transcription Factors and Mediator Establish Super-Enhancers at Key Cell Identity Genes
Whyte, W. A., Orlando, D. A., Hnisz, D., Abraham, B. J., Lin, C. Y., Kagey, M. H., Rahl, P. B., Lee, T. I., & Young, R. A. (2013) · Cell · doi:10.1016/j.cell.2013.03.035 · Cited by 4,143
Restoring function in exhausted CD8 T cells during chronic viral infection
Barber, D. L., Wherry, E. J., Masopust, D., Zhu, B., Allison, J. P., Sharpe, A. H., Freeman, G. J., & Ahmed, R. (2005) · Nature · doi:10.1038/nature04444 · Cited by 4,057
Self-citationSuper-enhancers in the control of cell identity and disease
Hnisz, D., Abraham, B. J., Lee, T. I., Lau, A., Saint-André, V., Sigova, A. A., Hoke, H. A., & Young, R. A. (2013) · Cell · doi:10.1016/j.cell.2013.09.053 · Cited by 3,662
Landscape of Infiltrating T Cells in Liver Cancer Revealed by Single-Cell Sequencing
Zheng, C., Zheng, L., Yoo, J.-K., Guo, H., Zhang, Y., Guo, X., Kang, B., Hu, R., Huang, J. Y., Zhang, Q., et al. (2017) · Cell · doi:10.1016/j.cell.2017.05.035 · Cited by 2,152
Viral Immune Evasion Due to Persistence of Activated T Cells Without Effector Function
Zajac, A. J., Blattman, J. N., Murali-Krishna, K., Sourdive, D. J. D., Suresh, M., Altman, J. D., & Ahmed, R. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.188.12.2205 · Cited by 1,978
Cited by
Sorted by citations
Items 701–800 of 1,001
Brunet‐Ratnasingham, E., Morou, A., Dubé, M., Niessl, J., Baxter, A. E., Tastet, O., Brassard, N., Ortega-Delgado, G.-G., Charlebois, R., Freeman, G. J., et al. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2022.104254 · Cited by 20
Metabolic and epigenetic orchestration of (CAR) T cell fate and function
Akbari, B., Hosseini, Z., Shahabinejad, P., Ghassemi, S., Mirzaei, H. R., & O’Connor, R. S. (2022) · Cancer Letters · doi:10.1016/j.canlet.2022.215948 · Cited by 20
Cellular milieu in clear cell renal cell carcinoma
Raghubar, A. M., Roberts, M. J., Wood, S., Healy, H. G., Kassianos, A. J., & Mallett, A. J. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.943583 · Cited by 20
Rational Protein Design Yields a CD20 CAR with Superior Antitumor Efficacy Compared with CD19 CAR
Chen, X., Chen, L. C., Khericha, M., Meng, X., Salvestrini, E., Shafer, A., Iyer, N., Alag, A. S., Ding, Y., Nicolaou, D. M., et al. (2022) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-22-0504 · Cited by 20
Wang, H., Tang, L. Y., Kong, Y., Liu, W., Zhu, X., & You, Y. H. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24119115 · Cited by 19
Mitra, A., Thompson, B., Strange, A., Amato, C. M., Vassallo, M., Dolgalev, I., Hester-McCullough, J., Muramatsu, T., Kimono, D. A., Puranik, A. S., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-0653 · Cited by 18
Ibrahim, M. L., Zheng, H., Barlow, M. L., Latif, Y., Chen, Z., Yu, X., & Beg, A. A. (2024) · The Journal of Immunology · doi:10.4049/jimmunol.2300475 · Cited by 19
The war between the immune system and the tumor - using immune biomarkers as tracers
Yang, K., Lu, R., Mei, J., Cao, K., Zeng, T., Hua, Y., Huang, X., Li, W., & Yin, Y. (2024) · Biomarker Research · doi:10.1186/s40364-024-00599-5 · Cited by 22
Dissecting the human immune system with single cell RNA sequencing technology
Xu, G., Liu, Y., Li, H., Liu, L., Zhang, S., & Zhang, Z. (2019) · Journal of Leukocyte Biology · doi:10.1002/jlb.5mr1019-179r · Cited by 19
Cheng, Y., Shao, Z., Chen, L., Zheng, Q., Zhang, Q., Ding, W., Zhang, M., Yu, Q., & Gao, D. (2020) · Immunology Letters · doi:10.1016/j.imlet.2020.11.004 · Cited by 20
New cytometry tools for immune monitoring during cancer immunotherapy
Sanjabi, S., & Lear, S. P. (2021) · Cytometry Part B Clinical Cytometry · doi:10.1002/cyto.b.21984 · Cited by 20
How Can We Engineer CAR T Cells to Overcome Resistance?
Glover, M., Avraamides, S., & Maher, J. F. (2021) · Biologics · doi:10.2147/btt.s252568 · Cited by 19
Weber, E. W., Lynn, R. C., Parker, K. R., Anbunathan, H., Lattin, J., Sotillo, E., Good, Z., Malipatlolla, M., Xu, P., Vandris, P., et al. (2020) · doi:10.1101/2020.01.26.920496 · Cited by 18
“Recent studies have identified TOX, TOX2, and AP-1 family members as central regulators of human T cell exhaustion that promote widespread transcriptional and epigenetic dysregulation (Alfei et al., 2019; Khan et al., 2019; Scott et al., 2019; Seo et al., 2019; Wang et al., 2019; Yao et al., 2019).”
BackgroundIRF4 impedes human CD8 T cell function and promotes cell proliferation and PD-1 expression
Hirsch, T., Neyens, D., Duhamel, C., Bayard, A., Vanhaver, C., Luyckx, M., de Oyanguren, F. S., Wildmann, C., Dauguet, N., Squifflet, J.-L., et al. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.114401 · Cited by 20
Heidari‐Foroozan, M., Rezalotfi, A., & Rezaei, N. (2024) · International Reviews of Immunology · doi:10.1080/08830185.2024.2401352 · Cited by 19
Pan, Q., Ding, L., Hladyshau, S., Yao, X., Zhou, J., Yan, L., Dhungana, Y., Shi, H., Qian, C., Dong, X., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-59620-6 · Cited by 24
CD4+ T cell dysfunction in cancer
Venkatesh, H., & Fong, L. H. (2025) · The Journal of Experimental Medicine · doi:10.1084/jem.20241417 · Cited by 19
CD49d marks Th1 and Tfh-like antigen-specific CD4+ T cells during Plasmodium chabaudi infection
Jian, J., Inoue, S., Bayarsaikhan, G., Miyakoda, M., Kimura, D., Kimura, K., Nozaki, E., Sakurai, T., Fernandez‐Ruiz, D., Heath, W. R., et al. (2021) · International Immunology · doi:10.1093/intimm/dxab020 · Cited by 18
The Natural History of T Cell Metabolism
Braun, M. Y. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22136779 · Cited by 18
Zoldan, K., Ehrlich, S., Killmer, S., Wild, K., Smits, M., Russ, M., Globig, A.-M., Hofmann, M., Thimme, R., & Boettler, T. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.742061 · Cited by 18
Dysfunctional State of T Cells or Exhaustion During Chronic Viral Infections and COVID-19: A Review
Mishra, K. P., Singh, M., Saraswat, D., Ganju, L., & Varshney, R. K. (2022) · Viral Immunology · doi:10.1089/vim.2022.0002 · Cited by 19
The TOX subfamily: all-round players in the immune system
Han, J., Wan, M., Ma, Z., & He, P. (2022) · Clinical & Experimental Immunology · doi:10.1093/cei/uxac037 · Cited by 18
Application of ATAC-seq in tumor-specific T cell exhaustion
Chen, C., Liu, J., Chen, Y., Lin, A., Mou, W., Zhu, L., Yang, T., Cheng, Q., Zhang, J., & Luo, P. (2022) · Cancer Gene Therapy · doi:10.1038/s41417-022-00495-w · Cited by 19
Proteomics of immune cells from liver tumors reveals immunotherapy targets
Canale, F. P., Neumann, J., von Renesse, J., Loggi, E., Pecoraro, M., Vogel, I. A., Zoppi, G., Antonini, G., Wolf, T., Jin, W., et al. (2023) · Cell Genomics · doi:10.1016/j.xgen.2023.100331 · Cited by 18
Parks, O. B., Eddens, T. J., Sojati, J., Lan, J., Zhang, Y., Oury, T. D., Ramsey, M. J., Erickson, J. J., Byersdorfer, C. A., & Williams, J. V. (2023) · Immunity & Ageing · doi:10.1186/s12979-023-00365-5 · Cited by 19
The transcription factor IRF4 determines the anti-tumor immunity of CD8+ T cells
Yan, H., Dai, Y., Zhang, X., Zhang, H., Xiao, X., Fu, J., Zou, D., Yu, A., Jiang, T., Li, X. C., et al. (2023) · iScience · doi:10.1016/j.isci.2023.108087 · Cited by 17
Zou, Y.-T., Li, J., Chai, J.-Y., Hu, Y., Zhang, W., & Zhang, Q. (2024) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2024.149513 · Cited by 20
Yu, T., der Jeught, K. V., Zhu, H., Zhou, Z., Sharma, S., Liu, S., Eyvani, H., So, K. M., Singh, N., Wang, J., et al. (2024) · Advanced Science · doi:10.1002/advs.202310308 · Cited by 20
Pace, L. (2021) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a037754 · Cited by 19
Tay, T., Bommakanti, G., Jaensch, E. S., Gorthi, A., Reddy, I. K., Hu, Y., Zhang, R., Doshi, A. S., Tan, S. L., Brucklacher-Waldert, V., et al. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101804 · Cited by 23
METTL3-VISTA axis-based combination immunotherapy for APC truncation colorectal cancer
Wu, L., Bai, R., Zhang, Y., Chen, H., Wu, J., Chen, Z., Wang, H., & Zhao, L. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-009865 · Cited by 18
Self-citationMontagne, J. M., Mitchell, J. T., Tandurella, J. A., Christenson, E. S., Danilova, L., Deshpande, A. M., Loth, M., Sidiropoulos, D. N., Davis-Marcisak, E. F., Bergman, D. R., et al. (2024) · iScience · doi:10.1016/j.isci.2024.111569 · Cited by 19
Side Effects of Immunosuppressant Drugs After Liver Transplant
Gabrielli, F., Bernasconi, E., Toscano, A., Avossa, A., Cavicchioli, A., Andreoné, P., & Gitto, S. (2025) · Pharmaceuticals · doi:10.3390/ph18030342 · Cited by 20
Yang, Y., Li, X., Liu, F., Ma, M., Yang, Y., Ruan, C., Lü, Y., Li, X., Wang, X., Shi, Y., et al. (2025) · JCI Insight · doi:10.1172/jci.insight.174600 · Cited by 19
Inherited mitochondrial genetics as a predictor of immune checkpoint inhibition efficacy in melanoma
Monson, K. R., Ferguson, R., Handzlik, J. E., Morales, L. J., Xiong, J., Chat, V., Dagayev, S., Khodadadi‐Jamayran, A., Simpson, D., Kazlow, E., et al. (2025) · Nature Medicine · doi:10.1038/s41591-025-03699-3 · Cited by 19
Immune correlates and mechanisms of TIL therapy efficacy: current insights and knowledge gaps
Rodrigo, B. N., Ortiz-Miranda, Y., Corría-Osorio, J., Coukos, G., & Harari, A. (2025) · Trends in cancer · doi:10.1016/j.trecan.2025.08.002 · Cited by 22
The ubiquitin ligase KLHL6 drives resistance to CD8+ T cell dysfunction
Cheng, H., Su, Y., Pan, X., Xu, Y., Xie, E., Du, J., Chen, D. G., Dai, X., Gottardo, R., Greenberg, P. D., et al. (2026) · Nature · doi:10.1038/s41586-025-09926-8 · Cited by 18
de Vos, L., Cano, T. M. C., Zarbl, R., Klümper, N., Ralser, D. J., Franzen, A., Herr, E., Gabrielpillai, J., Vogt, T. J., Dietrich, J., et al. (2022) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000429 · Cited by 18
TCF-1 regulates NKG2D expression on CD8 T cells during anti-tumor responses
Harris, R., Mammadli, M., Hiner, S., Suo, L., Yang, Q., Sen, J. M., & Karimi, M. A. (2022) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-022-03323-0 · Cited by 17
LAT1 enables T cell activation under inflammatory conditions
Ogbechi, J., Wright, H. L., Balint, S., Topping, L. M., Kristina, Z., Huang, Y.-S., Pantazi, E. D., Swart, M., Windell, D., Marin, E., et al. (2023) · Journal of Autoimmunity · doi:10.1016/j.jaut.2023.103031 · Cited by 17
Focus on T cell exhaustion: new advances in traditional Chinese medicine in infection and cancer
Li, S., Hao, L., Zhang, J., Deng, J., & Hu, X. (2023) · Chinese Medicine · doi:10.1186/s13020-023-00785-x · Cited by 17
Sézary syndrome originates from heavily mutated hematopoietic progenitors
Harro, C. M., Sprenger, K. B., Chaurio, R. A., Powers, J. J., Innamarato, P., Anadon, C. M., Zhang, Y., Biswas, S., Mandal, G., Mine, J. A., et al. (2023) · Blood Advances · doi:10.1182/bloodadvances.2022008562 · Cited by 20
Bossio, S., Abrate, C., Tosello, J., Rodríguez, C., Canale, F. P., Ramello, M. C., Brunotto, V., Richer, W., Rocha, D., Sedlik, C., et al. (2023) · OncoImmunology · doi:10.1080/2162402x.2023.2246319 · Cited by 18
Garman, B., Jiang, C., Daouti, S., Kumar, S., Mehta, P., Jacques, M. K., Menard, L. C., Manjarrez‐Orduño, N., Dolfi, S. C., Mukherjee, P., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1151748 · Cited by 18
Piroozkhah, M., Gholinezhad, Y., Piroozkhah, M., Shams, E., & Mojarad, E. N. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1298891 · Cited by 21
shRNA-mediated gene silencing of HDAC11 empowers CAR-T cells against prostate cancer
Zhang, H., Yao, J., Ajmal, I., Farooq, M. A., & Jiang, W. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1369406 · Cited by 17
Zhang, C., Gou, X., Lai, G., Li, K., Zhu, X., Liu, N., Kuang, Y., Ren, K., Xie, Y., Xu, Y., et al. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.217259 · Cited by 17
Ge, L., Wen, Z., & Xiong, S. (2025) · Cell Reports · doi:10.1016/j.celrep.2024.115128 · Cited by 17
Rosner, S., Connor, S. C., Sanber, K. S., ZAHURAK, M. L., Zhang, T., Gurumurthy, I., Zeng, Z., Presson, B., Singh, D., Rayes, R. F., et al. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-2983 · Cited by 18
Deciphering the role of histone modifications in memory and exhausted CD8 T cells
Huang, H., Baxter, A. E., Zhang, Z., Good, C. R., Alexander, K. A., Chen, Z., Garcia, P. A. A., Samareh, P., Collins, S. M., Glastad, K. M., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-99804-0 · Cited by 17
Self-citationWalsh, Z. H., Frangieh, C. J., Kothapalli, N., Levy, J. A., Heck, C., Melms, J. C., Gejman, R. S., Shah, P., Pollard, J. M., Naik, A., et al. (2025) · Cell · doi:10.1016/j.cell.2025.05.037 · Cited by 16
Liu, H., & Liang, Q. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1616794 · Cited by 19
Yuan, Y., Niu, Y., Huang, Z., Shi, Y., Zhu, L., Zuo, D., Zhong, C., Li, K., Guan, X., Yuan, Y., et al. (2025) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2510576122 · Cited by 16
Moustaki, A., Crawford, J. C., Alli, S., Fan, Y., Boi, S. K., Zamora, A. E., McDonald, N., Wu, G., Nakitandwe, J., Newman, S., et al. (2022) · Science Immunology · doi:10.1126/sciimmunol.abf6136 · Cited by 17
He, Q., Lu, Y., Tian, W., Jiang, R., Yu, W., Liu, Y., Sun, M., Wang, F., Zhang, H., Wu, N., et al. (2022) · Cellular and Molecular Immunology · doi:10.1038/s41423-022-00912-y · Cited by 16
The pleiotropic roles of EZH2 in T-cell immunity and immunotherapy
Wang, Y., Bui, T., & Zhang, Y. (2022) · International Journal of Hematology · doi:10.1007/s12185-022-03466-x · Cited by 17
Wu, Y., Kang, K., Chang, H., Wang, L., Wang, Z., & Zhao, A. (2023) · Biomolecules · doi:10.3390/biom13010185 · Cited by 16
Complementary HLH susceptibility factors converge on CD8 T-cell hyperactivation
Landy, E., Varghese, J., Dang, V., Szymczak-Workman, A. L., Kane, L., & Canna, S. (2023) · Blood Advances · doi:10.1182/bloodadvances.2023010502 · Cited by 16
Yang, Y., Wang, Y., Wang, Z., Yan, H., Gong, Y., Hu, Y., Jiang, Y., Wen, S., Xu, F., Wang, B., et al. (2024) · Nature Cell Biology · doi:10.1038/s41556-024-01351-9 · Cited by 18
TIGIT acts as an immune checkpoint upon inhibition of PD1 signaling in autoimmune diabetes
Trivedi, P., Jhala, G., George, D. J. D., Chiu, C. Y. H., Selck, C., Ge, T., Catterall, T., Elkerbout, L., Boon, L., Joller, N., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1370907 · Cited by 17
Advancing immunosuppression in liver transplantation: A narrative review
Iesari, S., Nava, F. L., Zais, I. E., Coubeau, L., Ferraresso, M., Favi, E., & Lerut, J. P. (2024) · Hepatobiliary & pancreatic diseases international · doi:10.1016/j.hbpd.2024.03.001 · Cited by 18
Yin, S., Li, C., Shen, X., Yu, G., Cui, L., Wu, Y., He, Y., Yu, S., Chen, J., Lu, S., et al. (2024) · Advanced Science · doi:10.1002/advs.202403438 · Cited by 15
Two parallel worlds of memory T cells
Chu, T., Berner, J., & Zehn, D. (2020) · Nature Immunology · doi:10.1038/s41590-020-00815-y · Cited by 16
Knuschke, T., Kollenda, S., Wenzek, C., Zelinskyy, G., Steinbach, P., Dittmer, U., Buer, J., Epple, M., & Westendorf, A. M. (2021) · mBio · doi:10.1128/mbio.02121-20 · Cited by 16
Barili, V., Vecchi, A. L., Rossi, M., Montali, I., Tiezzi, C., Penna, A., Laccabue, D., Missale, G., Fisicaro, P., & Boni, C. (2021) · Cells · doi:10.3390/cells10102563 · Cited by 18
Kim, H. J., Ban, J.-J., Kang, J., Im, H. W., Ko, S. H., Sung, J., Park, S., Park, J.-E., & Choi, S. J. (2024) · Brain Communications · doi:10.1093/braincomms/fcae428 · Cited by 16
Wei, K., Li, R., Zhao, X., Xie, B., Xie, T., Sun, Q., Chen, Y., Wei, P., Xu, W., Guo, X., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-56029-z · Cited by 14
Self-citationTherapeutic potential of targeting LAG-3 in cancer
Davar, D., Anderson, A. C., & Díaz-Padilla, I. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2025-011652 · Cited by 17
Bessler, N., Wezenaar, A. K. L., Ariese, H. C., Honhoff, C., Dommann, N., Wehrens, E. J., Ruiz-Moreno, C., van den Broek, T. J. M., Collot, R. V. U., Kloosterman, D. J., et al. (2026) · Nature Cancer · doi:10.1038/s43018-025-01084-0 · Cited by 16
Stromnes, I. M., Hulbert, A., Rollins, M. R., Basom, R., Delrow, J. J., Bonson, P., Burrack, A. L., Hingorani, S. R., & Greenberg, P. D. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003525 · Cited by 16
Autoreactive CD8 T cells in NOD mice exhibit phenotypic heterogeneity but restricted TCR gene usage
Kasmani, M. Y., Ciecko, A. E., Brown, A. K., Петрова, Г. В., Gorski, J., Chen, Y., & Cui, W. (2022) · Life Science Alliance · doi:10.26508/lsa.202201503 · Cited by 14
The landscape of chimeric antigen receptor T cell therapy in breast cancer: Perspectives and outlook
Zhang, H., Zhu, S., Deng, W., Li, R., Zhou, H., & Xiong, H. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.887471 · Cited by 19
Epigenetic engineering for optimal chimeric antigen receptor T cell therapy
Ito, Y., & Kagoya, Y. (2022) · Cancer Science · doi:10.1111/cas.15541 · Cited by 14
Strong Basal/Tonic TCR Signals Are Associated with Negative Regulation of Naive CD4+ T Cells
Zinzow-Kramer, W. M., Kolawole, E. M., Eggert, J., Evavold, B. D., Scharer, C. D., & Au‐Yeung, B. B. (2022) · ImmunoHorizons · doi:10.4049/immunohorizons.2200051 · Cited by 15
Kennedy, B. C., Dean, I., & Withers, D. R. (2023) · Discovery Immunology · doi:10.1093/discim/kyad004 · Cited by 15
Increased NKG2A+CD8+ T-cell exhaustion in patients with adenomyosis
Liu, W., Sheng, S., Zhu, C., Li, C., Zou, Y., Yang, C., Chen, Z., Wang, F., & Jiao, X. (2023) · Mucosal Immunology · doi:10.1016/j.mucimm.2023.02.003 · Cited by 15
Jang, H. J., Caron, C., Lee, C. K., Wang, L., Jama, B., Bui, J. D., & Morris, G. P. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-006472 · Cited by 15
Wang, Y., He, S., Calendo, G., Bui, T., Tian, Y., Lee, C. Y., Zhou, Y., Zhao, X., Abraham, C., Mo, W., et al. (2023) · Blood · doi:10.1182/blood.2023021126 · Cited by 15
TOX3 deficiency mitigates hyperglycemia by suppressing hepatic gluconeogenesis through FoxO1
Liu, C., Zheng, Y., Hu, S., Liang, X., Li, Y., Yu, Z., Liu, Y., Bian, Y., Man, Y., Zhao, S., et al. (2023) · Metabolism · doi:10.1016/j.metabol.2023.155766 · Cited by 15
Durand, A., Bonilla, N., Level, T., Ginestet, Z., Lombès, A., Guichard, V., Germain, M., Jacques, S., Letourneur, F., Cruzeiro, M. D., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-45984-8 · Cited by 20
Arnold, F., Kupferschmid, L., Weissenborn, P., Heldmann, L., Hummel, J. F., Zareba, P., Sagar, Rogg, M., Schell, C., & Tanriver, Y. (2024) · Cellular and Molecular Immunology · doi:10.1038/s41423-024-01197-z · Cited by 15
Enhanced tumor response to adoptive T cell therapy with PHD2/3-deficient CD8 T cells
Dvořáková, T., Finisguerra, V., Formenti, M., Loriot, A. E., Boudhan, L., Zhu, J., & den Eynde, B. J. V. (2024) · Nature Communications · doi:10.1038/s41467-024-51782-z · Cited by 17
Prognostic Biomarkers for Melanoma Immunotherapy
Twitty, C., Huppert, L. A., & DAUD, A. I. (2020) · Current Oncology Reports · doi:10.1007/s11912-020-0886-z · Cited by 15
Harnessing CD8+ T‐cell exhaustion to treat type 1 diabetes
Kwong, C.-T. J., Selck, C., Tahija, K., McAnaney, L. J., Le, D. V., Kay, T. W. H., Thomas, H. E., & Krishnamurthy, B. (2021) · Immunology and Cell Biology · doi:10.1111/imcb.12444 · Cited by 15
Liu, Z., Wu, A., Wu, Z., Wang, T., Pan, Y., Li, B., Zhang, X., & Yu, M. (2021) · Communications Biology · doi:10.1038/s42003-022-03214-1 · Cited by 15
TOX promotes follicular helper T cell differentiation in patients with primary Sjögren’s syndrome
Liu, S., Yang, Y., Zeng, L., Wang, L., He, C., Chen, Z., Sun, J., Lyu, T., Wang, M., Chen, H., et al. (2022) · Lara D. Veeken · doi:10.1093/rheumatology/keac304 · Cited by 15
Epigenetics in T-cell driven inflammation and cancer
Falkowski, L., Buddenkotte, J., & Datsi, A. (2023) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2023.01.008 · Cited by 15
T-cell exhaustion in multiple myeloma
Żyłka, K., Kubicki, T., Gil, L., & Dytfeld, D. (2024) · Expert Review of Hematology · doi:10.1080/17474086.2024.2370552 · Cited by 15
Lin, Y., Ruze, R., Zhang, R., Tuergan, T., Wang, M., Tulahong, A., Zhu, D., Yuan, Z., Jiang, T., Aji, T., et al. (2024) · Liver Cancer · doi:10.1159/000542578 · Cited by 17
Mechanisms of T-cell Depletion in Tumors and Advances in Clinical Research
Su, X., Zhang, M., Zhu, H., Cai, J., Wang, Z., Xu, Y., Wang, L., Shen, C., & Cai, M. M. (2025) · Biological Procedures Online · doi:10.1186/s12575-025-00265-6 · Cited by 14
New insights on potency assays from recent advances and discoveries in CAR T-cell therapy
Shao, L., Zheng, Y., Somerville, R. P. T., Stroncek, D. F., & Jin, P. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1597888 · Cited by 16
Liu, G., Tian, X., Wang, Q., Xu, S., Jiang, Y., Gao, Y., & Wu, Y. (2025) · Science Advances · doi:10.1126/sciadv.adx9221 · Cited by 16
Loss of YTHDF2 enhances Th9 programming and CAR-Th9 cell antitumor efficacy
Xiao, S. J., Duan, S., Ya-qun, H., Zhang, J., Ma, S., Caligiuri, M. A., & Yu, J. (2025) · Nature Immunology · doi:10.1038/s41590-025-02235-2 · Cited by 14
Li, R., Wei, K., Sun, Q., Xie, B., Wei, P., Xie, T., Guo, X., Chen, Y., Pan, B., Zhao, Z., et al. (2025) · Nature Immunology · doi:10.1038/s41590-025-02330-4 · Cited by 18
BACH2 dosage establishes the hierarchy of stemness and fine-tunes antitumor immunity in CAR T cells
Hu, T., Zhu, Z., Ying, L., Wizzard, S., Hoar, J., Shinde, S. S., Yihunie, K. D., Yao, C., & Wu, T. (2026) · Nature Immunology · doi:10.1038/s41590-025-02388-0 · Cited by 16
Kimura, Y., Sumiyoshi, M., & Taniguchi, M. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.110077 · Cited by 14
Translational considerations for immunotherapy clinical trials in pediatric neuro-oncology
Foster, J., Alonso, M. M., Sayour, E. J., Davidson, T. B., Persson, M. L., Dun, M. D., Kline, C., Mueller, S., Vitanza, N. A., & van der Lugt, J. (2023) · Neoplasia · doi:10.1016/j.neo.2023.100909 · Cited by 14
Tian, W., Qin, G., Jia, M., Li, W., Cai, W., Wang, H., Zhao, Y., Bao, X., Wei, W., Zhang, Y., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1198551 · Cited by 16
Lee, S., Lee, K., Bae, H., Lee, K., Lee, J., Ma, J., Lee, Y. J., Lee, B. R., Park, W., & Im, S. J. (2023) · Nature Communications · doi:10.1038/s41467-023-41357-9 · Cited by 14
Smith, A. L., Skupa, S. A., Eiken, A. P., Reznicek, T. E., Schmitz, E. G., Williams, N., Moore, D. Y., D'Angelo, C. R., Kallam, A., Lunning, M. A., et al. (2024) · JCI Insight · doi:10.1172/jci.insight.177054 · Cited by 14
Metadata
- Authors
- Khan, O., Giles, J. R., McDonald, S., Manne, S., Ngiow, S. F., Patel, K. P., Werner, M. T., Huang, A. C., Alexander, K. A., Wu, J. E., Attanasio, J., Yan, P., George, S. M., Bengsch, B., Staupe, R. P., Donahue, G., Xu, W., Amaravadi, R. K., Xu, X., Karakousis, G. C., Mitchell, T. C., Schuchter, L. M., Kaye, J., Berger, S. L., & Wherry, E. J.
- Affiliations
- Arsenal Biosciences (United States) (US)
- University of Pennsylvania (US)
- University of Freiburg (DE)
- Abramson Cancer Center (US)
- Cedars-Sinai Medical Center (US)
- Parker Institute for Cancer Immunotherapy (US)
- Corresponding author
- Wherry, E. John
- ORCID
- Khan, Omar
- Giles, Josephine R.
- McDonald, Sierra
- Manne, Sasikanth
- Ngiow, Shin Foong
- Patel, Kunal P.
- Werner, Michael T.
- Huang, Alexander C.
- Alexander, Katherine A.
- Wu, Jennifer E.
- Attanasio, John
- Yan, Patrick
- Bengsch, Bertram
- Staupe, Ryan P.
- Donahue, Greg
- Xu, Wei
- Amaravadi, Ravi K.
- Xu, Xiaowei
- Karakousis, Giorgos C.
- Mitchell, Tara C.
- Schuchter, Lynn M.
- Kaye, Jonathan
- Berger, Shelley L.
- Wherry, E. John
- Venue
- Nature
- Published
- 2019-06-17
- Volume
- 571
- Issue
- 7764
- Pages
- 211-218
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC6713202
- OpenAlex
- W2952815301
- Cited by
- 1,646
- References
- 63
- Citations by year
- 2026: 258 · 2025: 249 · 2024: 234 · 2023: 252 · 2022: 211 · 2021: 235 · 2020: 161 · 2019: 43
- FWCI
- 64.93
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Cold Spring Harbor Laboratory Institutional Repository (Cold Spring Harbor Laboratory) (acceptedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- National Cancer Institute (R01CA078831, F32CA221010, P30CA010815, P01CA210944)
- National Institute of Allergy and Infectious Diseases (R01AI115712, R01AI054977, R01AI105343, F30AI129263, U19AI117950, U19AI082630, P01AI108545)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Signaling Pathways in Disease
- Keywords
- TOX transcription factor, CD8+ T cell exhaustion, chromatin landscape, epigenetic regulation, calcineurin, NFATc1, feed-forward loop, inhibitory receptors, chronic infection, cancer immunotherapy, checkpoint blockade, transcriptional programs
- MeSH terms
- Animals, Epistasis, Genetic, Female, Gene Expression Regulation, Genotype, Immunologic Memory, Male, Mice, Inbred BALB C, Mice, Inbred C57BL, Transcription, Genetic, Homeodomain Proteins, CD8-Positive T-Lymphocytes, Tumor Escape, Calcineurin, Calcium Signaling, Feedback, Physiological, NFATC Transcription Factors, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
